Skip to content

Clinical application of remazolam combined with afentanil intravenous anesthesia in painless gastroenteroscopy

Clinical application of remazolam combined with afentanil intravenous anesthesia in painless gastroenteroscopy

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400086777
Enrollment
Unknown
Registered
2024-07-10
Start date
2024-07-20
Completion date
Unknown
Last updated
2024-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Painless endoscopic treatment

Interventions

Group P:The anesthetic regimen was propofol 1.5mg/kg + alfentanil 6µg/kg, and the supplemental regimen was propofol 0.5 mg/kg
Group R:The anesthetic regimen was remazolam 0.2mg/kg+ afentanil 6µg/kg, and the supplemental regimen was remazolam 2.5 mg/bolus
Group PR:The anesthetic regimen was propofol 0.5mg/kg + Remazolam 0.15mg/kg+ afentanil 6µg/kg, and the supplemental regimen was propofol 0.5mg/kg

Sponsors

The Second People's Hospital of Hefei
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients undergoing painless gastroscopy at selected times; Age 60~80 years old; American Anesthesiologist Association (ASA) grade I to III; Body mass index (BMI) 18-28 kg/m2.

Exclusion criteria

Exclusion criteria: Severe hypertension or diabetes; Coronary heart disease; Combined with central nervous system disease; Difficult airway; Allergic to the investigational drug; Intermittent or long-term use of benzodiazepines or opioids within 2 months before admission.

Design outcomes

Primary

MeasureTime frame
mean blood pressure;Occurrence of complications;

Secondary

MeasureTime frame
The depth of anesthesia is as long as required for surgery;Ramsay score, Aldrete score;

Countries

China

Contacts

Public ContactHongjian Wang

The Second People's Hospital of Hefei

wanghj_a@163.com+86 158 0601 9263

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026